{"id":"W4388738310","doi":"10.1097/01.hs9.0000936164.84357.ed","title":"P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Internal medicine; Multiple myeloma; Clinical endpoint; Dexamethasone; Surgery; Phases of clinical research; Minimal residual disease; Progression-free survival; Oncology; Gastroenterology; Chemotherapy; Randomized controlled trial; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003307183,0.0006997728,0.001883915,0.0003348639,0.0002889627,0.00101272,0.0006881547,0.0004833757,0.001452253],"category_scores_gemma":[0.001614373,0.0003725205,0.002669725,0.000438017,0.0004291017,0.0006501011,0.0004727909,0.002073653,0.0002346738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007468021,"about_ca_system_score_gemma":0.0009399985,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005119924,"about_ca_topic_score_gemma":0.001659999,"domain_scores_codex":[0.9990828,0.0005338494,0.00007341356,0.0001324382,0.00008603387,0.00009150662],"domain_scores_gemma":[0.9984005,0.0004835305,0.0005378238,0.0001346193,0.00006635612,0.000377108],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8547403,0.008501855,0.05385855,0.0005325411,0.00601447,0.0001044252,0.000144813,0.001991461,0.008755135,0.0001611988,0.001609572,0.0635857],"study_design_scores_gemma":[0.3318766,0.421165,0.2219378,0.0001527235,0.01072224,0.000488846,0.0001356891,0.004140762,0.003833962,0.000540457,0.00492232,0.0000836058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946797,0.003405114,0.0002391808,0.0001958611,0.00006672252,0.0002387701,0.0006474137,0.00001478566,0.0005123224],"genre_scores_gemma":[0.9966209,0.0008794711,0.0004806225,0.0002905402,0.0001021384,0.0002623087,0.001049322,0.000005926239,0.0003086211],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003307183,"threshold_uncertainty_score":0.01749027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02799922324280263,"score_gpt":0.3080481877675247,"score_spread":0.2800489645247221,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}